Alzheimer's Blood Tests After a Borderline Result: What Questions Should the Follow-Up Visit Answer? The follow-up visit should answer whether Alzheimer pathology is likely, what else could explain the result, and whether you need spinal-fluid testing, a brain scan, or a timed recheck. A borderline result means an intermediate or indeterminate amyloid-pathology risk, not a yes or no. That category comes from FDA-cleared blood tests that use two cutoffs to report positive, intermediate, or negative risk, according to Roche in the FDA clearance announcement. It signals uncertainty that needs clinical context and a clear next step.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does borderline mean?
- How likely was Alzheimer's before the test?
- Could kidneys, stroke, or heart disease affect the number?
- Do you need PET or spinal-fluid confirmation?
- Is this blood test strong enough to decide alone?
What does borderline mean?
Borderline means your p-tau217 value fell between the low and high cutoffs. It does not confirm or rule out amyloid buildup. Roche says an indeterminate result leaves the expected amyloid PET or spinal-fluid result uncertain.
A widely studied approach sets those cutoffs at 95% sensitivity and 95% specificity, according to JAMA researchers in the JAMA study. Values between the lines are labeled intermediate. Only that middle group moves on to confirmatory testing.
How likely was Alzheimer's before the test?
The visit should start with a full clinical review. That includes memory history, daily function, medications, neurologic exam, and prior brain imaging. The Alzheimer's Association guideline says testing must follow comprehensive evaluation and use each patient's pretest probability.
Ask what pointed toward Alzheimer's before blood was drawn. Ask what points away from it now. A borderline result carries different weight with classic progressive memory loss than with stable mild complaints.
Could kidneys, stroke, or heart disease affect the number?
Yes, and the visit should check. Chronic kidney disease, stroke, and prior heart attack can raise plasma p-tau without Alzheimer pathology, according to Mayo Clinic findings reported in the Mayo Clinic summary. A borderline positive deserves kidney-function and comorbidity review.
Bring recent creatinine, estimated glomerular filtration rate, stroke history, and cardiac history. Ask whether dehydration, new medications, or acute illness coincided with the draw. Fixing the context can prevent a false-positive label.
Do you need PET or spinal-fluid confirmation?
For mild cognitive impairment with intermediate risk, doctors often reserve amyloid PET or cerebrospinal-fluid testing for this group. That focused approach limits invasive testing to patients where it changes care.
Ask directly whether treatment eligibility in your case requires confirmed amyloid. Australian clinicians note two practical paths for borderline cases: repeat the blood test in about 12 months or proceed to PET or spinal-fluid testing sooner, especially when treatment depends on proof of amyloid, as explained in the clinician guide. Use the visit to choose one path and set a date.
- Confirm treatment plans that require proven amyloid
- Decide between timed blood retest and prompt PET or spinal-fluid testing
- List symptoms or test changes that would move the date earlier
Is this blood test strong enough to decide alone?
Ask which assay was used and whether it meets high-accuracy standards. Clinical Lab Products, describing the 2025 Association guideline, reports triage tests need at least 90% sensitivity and 75% specificity, while stand-alone confirmatory tests need at least 90% for both. A borderline result from a triage test is a prompt for follow-up, not a final diagnosis.
Also ask how the lab defines its middle zone. Different assays set different cutoffs and handle the gray zone differently. Write down the exact test name, result value, cutoff range, and planned next test before you leave.
You Might Also Like
- Safety Questions After the 2026 LiBBY Dementia Trial: Questions Family Caregivers Can Ask About the Research
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Questions Family Caregivers Can Ask About the Research
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: Questions Family Caregivers Can Ask About the Research
